If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

During an investor presentation Thursday, executives admitted to being overly optimistic their vaccine could wrest significant market share away from GSK's and Pfizer's products this year.

Analyst Graham Parry of Bank of America Securities maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), retaining the ...

A UPMC pulmonologist discusses RSV, including what the symptoms are, who is most at risk and how effective the vaccine is.

Covid vaccine maker Moderna plans to sextuple the number of products it has approved over the next three years, the company ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Moderna Inc. aims to reduce its research and development budget by about 20% over the next three years as the biotech tries ...

Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...

Moderna’s stock has seen an extended downtrend since peaking above $480 in late 2021. After crashing to below $70 in November last year, the stock experienced a strong medium-term rally that took it ...